vs
Side-by-side financial comparison of ENNIS, INC. (EBF) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
ENNIS, INC. is the larger business by last-quarter revenue ($100.2M vs $86.8M, roughly 1.2× IOVANCE BIOTHERAPEUTICS, INC.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs 0.4%). ENNIS, INC. produced more free cash flow last quarter ($15.7M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 1.4%).
ENNIS, INC. (ticker EBF) is a leading North American provider of printed business products and related services. Its offerings include custom business forms, pressure-sensitive labels, marketing collateral, promotional items, and branded packaging, serving clients across retail, healthcare, financial services, and small business segments.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
EBF vs IOVA — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $100.2M | $86.8M |
| Net Profit | $10.8M | — |
| Gross Margin | 31.9% | 67.4% |
| Operating Margin | 15.0% | -84.7% |
| Net Margin | 10.8% | — |
| Revenue YoY | 0.4% | 17.7% |
| Net Profit YoY | 6.1% | — |
| EPS (diluted) | $0.42 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $100.2M | $86.8M | ||
| Q3 25 | $98.7M | $67.5M | ||
| Q2 25 | $97.2M | $60.0M | ||
| Q1 25 | $92.7M | $49.3M | ||
| Q4 24 | $99.8M | $73.7M | ||
| Q3 24 | $99.0M | $58.6M | ||
| Q2 24 | $103.1M | $31.1M | ||
| Q1 24 | $97.4M | $715.0K |
| Q4 25 | $10.8M | — | ||
| Q3 25 | $13.2M | $-91.3M | ||
| Q2 25 | $9.8M | $-111.7M | ||
| Q1 25 | $9.0M | $-116.2M | ||
| Q4 24 | $10.2M | — | ||
| Q3 24 | $10.3M | $-83.5M | ||
| Q2 24 | $10.7M | $-97.1M | ||
| Q1 24 | $10.1M | $-113.0M |
| Q4 25 | 31.9% | 67.4% | ||
| Q3 25 | 30.5% | 43.0% | ||
| Q2 25 | 31.1% | 5.5% | ||
| Q1 25 | 29.5% | -0.8% | ||
| Q4 24 | 29.3% | 68.7% | ||
| Q3 24 | 30.1% | 46.2% | ||
| Q2 24 | 30.0% | -0.8% | ||
| Q1 24 | 28.4% | — |
| Q4 25 | 15.0% | -84.7% | ||
| Q3 25 | 12.5% | -140.7% | ||
| Q2 25 | 13.7% | -189.8% | ||
| Q1 25 | 13.0% | -245.8% | ||
| Q4 24 | 13.1% | -117.5% | ||
| Q3 24 | 13.3% | -152.1% | ||
| Q2 24 | 13.3% | -327.6% | ||
| Q1 24 | 13.3% | -16464.6% |
| Q4 25 | 10.8% | — | ||
| Q3 25 | 13.3% | -135.3% | ||
| Q2 25 | 10.1% | -186.2% | ||
| Q1 25 | 9.7% | -235.5% | ||
| Q4 24 | 10.2% | — | ||
| Q3 24 | 10.4% | -142.7% | ||
| Q2 24 | 10.4% | -312.2% | ||
| Q1 24 | 10.4% | -15800.8% |
| Q4 25 | $0.42 | — | ||
| Q3 25 | $0.51 | — | ||
| Q2 25 | $0.38 | $-0.33 | ||
| Q1 25 | $0.34 | $-0.36 | ||
| Q4 24 | $0.39 | $-0.24 | ||
| Q3 24 | $0.40 | $-0.28 | ||
| Q2 24 | $0.41 | $-0.34 | ||
| Q1 24 | $0.39 | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $31.3M | $297.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $304.8M | $698.6M |
| Total Assets | $354.3M | $913.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $31.3M | $297.0M | ||
| Q3 25 | $31.9M | $300.8M | ||
| Q2 25 | $32.6M | $301.2M | ||
| Q1 25 | $72.5M | $359.7M | ||
| Q4 24 | $68.6M | $323.8M | ||
| Q3 24 | $122.6M | $397.5M | ||
| Q2 24 | $123.7M | $412.5M | ||
| Q1 24 | $110.9M | $356.2M |
| Q4 25 | $304.8M | $698.6M | ||
| Q3 25 | $305.4M | $702.3M | ||
| Q2 25 | $301.2M | $698.5M | ||
| Q1 25 | $302.0M | $767.9M | ||
| Q4 24 | $297.7M | $710.4M | ||
| Q3 24 | $358.4M | $773.5M | ||
| Q2 24 | $354.4M | $768.5M | ||
| Q1 24 | $349.8M | $680.0M |
| Q4 25 | $354.3M | $913.2M | ||
| Q3 25 | $361.8M | $904.9M | ||
| Q2 25 | $361.7M | $907.4M | ||
| Q1 25 | $348.9M | $966.7M | ||
| Q4 24 | $346.1M | $910.4M | ||
| Q3 24 | $406.8M | $991.1M | ||
| Q2 24 | $406.2M | $964.3M | ||
| Q1 24 | $399.2M | $869.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $16.4M | $-52.6M |
| Free Cash FlowOCF − Capex | $15.7M | $-61.9M |
| FCF MarginFCF / Revenue | 15.7% | -71.3% |
| Capex IntensityCapex / Revenue | 0.7% | 10.7% |
| Cash ConversionOCF / Net Profit | 1.52× | — |
| TTM Free Cash FlowTrailing 4 quarters | $42.5M | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $16.4M | $-52.6M | ||
| Q3 25 | $10.5M | $-78.7M | ||
| Q2 25 | $8.0M | $-67.4M | ||
| Q1 25 | $12.8M | $-103.7M | ||
| Q4 24 | $18.2M | $-73.3M | ||
| Q3 24 | $11.8M | $-59.0M | ||
| Q2 24 | $23.1M | $-98.4M | ||
| Q1 24 | $16.6M | $-122.3M |
| Q4 25 | $15.7M | $-61.9M | ||
| Q3 25 | $9.0M | $-89.5M | ||
| Q2 25 | $6.6M | $-74.9M | ||
| Q1 25 | $11.1M | $-109.9M | ||
| Q4 24 | $17.5M | $-77.5M | ||
| Q3 24 | $10.7M | $-61.3M | ||
| Q2 24 | $20.6M | $-98.9M | ||
| Q1 24 | $15.0M | $-126.5M |
| Q4 25 | 15.7% | -71.3% | ||
| Q3 25 | 9.2% | -132.7% | ||
| Q2 25 | 6.8% | -124.9% | ||
| Q1 25 | 12.0% | -222.8% | ||
| Q4 24 | 17.6% | -105.1% | ||
| Q3 24 | 10.8% | -104.6% | ||
| Q2 24 | 20.0% | -317.9% | ||
| Q1 24 | 15.3% | -17685.3% |
| Q4 25 | 0.7% | 10.7% | ||
| Q3 25 | 1.4% | 16.1% | ||
| Q2 25 | 1.4% | 12.4% | ||
| Q1 25 | 1.8% | 12.6% | ||
| Q4 24 | 0.6% | 5.7% | ||
| Q3 24 | 1.1% | 3.9% | ||
| Q2 24 | 2.4% | 1.4% | ||
| Q1 24 | 1.7% | 583.4% |
| Q4 25 | 1.52× | — | ||
| Q3 25 | 0.80× | — | ||
| Q2 25 | 0.81× | — | ||
| Q1 25 | 1.41× | — | ||
| Q4 24 | 1.78× | — | ||
| Q3 24 | 1.15× | — | ||
| Q2 24 | 2.16× | — | ||
| Q1 24 | 1.63× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EBF
Segment breakdown not available.
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
